278 related articles for article (PubMed ID: 27982586)
1. Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
Kurochkin IV; Guarnera E; Wong JH; Eisenhaber F; Berezovsky IN
Biochemistry; 2017 Jan; 56(1):228-239. PubMed ID: 27982586
[TBL] [Abstract][Full Text] [Related]
2. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.
Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A
J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867
[TBL] [Abstract][Full Text] [Related]
3. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme.
McCord LA; Liang WG; Dowdell E; Kalas V; Hoey RJ; Koide A; Koide S; Tang WJ
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13827-32. PubMed ID: 23922390
[TBL] [Abstract][Full Text] [Related]
4. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
Shen Y; Joachimiak A; Rosner MR; Tang WJ
Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
[TBL] [Abstract][Full Text] [Related]
5. Multiple allosteric sites are involved in the modulation of insulin-degrading-enzyme activity by somatostatin.
Tundo GR; Di Muzio E; Ciaccio C; Sbardella D; Di Pierro D; Polticelli F; Coletta M; Marini S
FEBS J; 2016 Oct; 283(20):3755-3770. PubMed ID: 27579517
[TBL] [Abstract][Full Text] [Related]
6. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
7. Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease.
Kurochkin IV; Guarnera E; Berezovsky IN
Trends Pharmacol Sci; 2018 Jan; 39(1):49-58. PubMed ID: 29132916
[TBL] [Abstract][Full Text] [Related]
8. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein.
Farris W; Mansourian S; Leissring MA; Eckman EA; Bertram L; Eckman CB; Tanzi RE; Selkoe DJ
Am J Pathol; 2004 Apr; 164(4):1425-34. PubMed ID: 15039230
[TBL] [Abstract][Full Text] [Related]
9. Insulysin: an allosteric enzyme as a target for Alzheimer's disease.
Song ES; Hersh LB
J Mol Neurosci; 2005; 25(3):201-6. PubMed ID: 15800373
[TBL] [Abstract][Full Text] [Related]
10. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
Im H; Manolopoulou M; Malito E; Shen Y; Zhao J; Neant-Fery M; Sun CY; Meredith SC; Sisodia SS; Leissring MA; Tang WJ
J Biol Chem; 2007 Aug; 282(35):25453-63. PubMed ID: 17613531
[TBL] [Abstract][Full Text] [Related]
11. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.
Llovera RE; de Tullio M; Alonso LG; Leissring MA; Kaufman SB; Roher AE; de Prat Gay G; Morelli L; Castaño EM
J Biol Chem; 2008 Jun; 283(25):17039-48. PubMed ID: 18411275
[TBL] [Abstract][Full Text] [Related]
12. The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design.
Tundo GR; Grasso G; Persico M; Tkachuk O; Bellia F; Bocedi A; Marini S; Parravano M; Graziani G; Fattorusso C; Sbardella D
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892174
[TBL] [Abstract][Full Text] [Related]
13. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
[TBL] [Abstract][Full Text] [Related]
14. Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Haque R; Nazir A
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2454-2462. PubMed ID: 27443962
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
Guo Q; Manolopoulou M; Bian Y; Schilling AB; Tang WJ
J Mol Biol; 2010 Jan; 395(2):430-43. PubMed ID: 19896952
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations reveal a novel mechanism for ATP inhibition of insulin degrading enzyme.
da Cruz CH; Seabra G
J Chem Inf Model; 2014 May; 54(5):1380-90. PubMed ID: 24697863
[TBL] [Abstract][Full Text] [Related]
17. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ; Folstein MF
Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.
Del Campo M; Stargardt A; Veerhuis R; Reits E; Teunissen CE
Neurosci Lett; 2015 Mar; 589():47-51. PubMed ID: 25597881
[TBL] [Abstract][Full Text] [Related]
19. Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-β Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimer's Disease.
Li G; Kim C; Kim J; Yoon H; Zhou H; Kim J
J Alzheimers Dis; 2015; 46(1):109-22. PubMed ID: 25720399
[TBL] [Abstract][Full Text] [Related]
20. Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Çakir B; Dağliyan O; Dağyildiz E; Bariş İ; Kavakli IH; Kizilel S; Türkay M
PLoS One; 2012; 7(2):e31787. PubMed ID: 22355395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
